secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001193125-24-275844
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx reports positive Phase 2 anito-cel data for relapsed/refractory multiple myeloma at ASH 2024
--------------------------------------------------------------------------------

- Hosted investor webcast at ASH highlighting new positive data from Phase 2 pivotal iMMagine-1 study of anito-cel.
- Study evaluates anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma.
- Filing notes data as positive but does not disclose specific efficacy or safety numbers.
- Corporate presentation attached as Exhibit 99.1 provides further details not included in this summary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524275844/0001193125-24-275844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524275844/d844330d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-275844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer